# SWOG Cancer Research Network

Source: https://onco.cc/companies/swog/  
OnCo record `swog` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SWOG is one of the US National Cancer Institute's cooperative groups: thousands of community and academic sites running practice-changing trials, including the 2026 first-line Hodgkin lymphoma result.

## Summary

Founded 1956 (Southwest Oncology Group). NCI National Clinical Trials Network member with >12,000 members at >1,300 sites. Landmark trials include S1826 (nivolumab-AVD in advanced Hodgkin lymphoma, FDA approval March 2026), S1418/BR006 (adjuvant pembrolizumab in TNBC), and the de-escalation trial SCARLET (S2212) in stage II-III TNBC. Statistical centre at Fred Hutchinson Cancer Center.

## Fields

- Kind: Company
- Last checked: 2026-09-06
- Also known as: SWOG; Southwest Oncology Group
- Tags: cooperative-group
- HQ: Portland, OR
- Type: cooperative-group
- Website: https://www.swog.org

## Notes

- NCTN cooperative group
- S1826 Hodgkin lymphoma
- SCARLET S2212 (TNBC de-escalation)
- Cancer control and survivorship

## Sources

- Official website: https://www.swog.org

## Connected records

- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/)
- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Melanoma](https://onco.cc/cancers/melanoma/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- institutions: [Fred Hutchinson Cancer Center](https://onco.cc/institutions/fred-hutch/), [Herbert Irving Comprehensive Cancer Center, Columbia University](https://onco.cc/institutions/columbia-hicc/), [Huntsman Cancer Institute, University of Utah](https://onco.cc/institutions/huntsman/), [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/), [OHSU Knight Cancer Institute](https://onco.cc/institutions/ohsu-knight/), [The University of Kansas Cancer Center](https://onco.cc/institutions/ku-cancer-center/), [UC Davis Comprehensive Cancer Center](https://onco.cc/institutions/uc-davis-cancer/), [USC Norris Comprehensive Cancer Center](https://onco.cc/institutions/usc-norris/), [Winship Cancer Institute of Emory University](https://onco.cc/institutions/emory-winship/)
- trials: [ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)](https://onco.cc/trials/alchemist/), [DART (SWOG S1609): nivolumab plus ipilimumab in rare tumours](https://onco.cc/trials/dart-s1609/), [DRAMMATIC](https://onco.cc/trials/drammatic/), [INT-0116 (Macdonald trial)](https://onco.cc/trials/int-0116/), [Lung-MAP (SWOG S1400 and S1900)](https://onco.cc/trials/lung-map/), [Lung-MAP S1400I: nivolumab with or without ipilimumab](https://onco.cc/trials/lung-map-s1400i/), [Lung-MAP S1800A: ramucirumab plus pembrolizumab](https://onco.cc/trials/lung-map-s1800a/), [SCARLET (SWOG S2212)](https://onco.cc/trials/scarlet-s2212/), [SWOG S0809](https://onco.cc/trials/swog-s0809/), [SWOG S1418 / NRG BR006](https://onco.cc/trials/swog-s1418/), [SWOG S1505](https://onco.cc/trials/swog-s1505/), [SWOG S1801](https://onco.cc/trials/swog-s1801/), [SWOG S1826](https://onco.cc/trials/swog-s1826/)
- people: [Alex F. Herrera](https://onco.cc/people/alex-herrera/), [Anne C. Chiang](https://onco.cc/people/anne-chiang/), [Charles D. Blanke](https://onco.cc/people/charles-blanke/), [Dawn L. Hershman](https://onco.cc/people/dawn-hershman/), [Hagen F. Kennecke](https://onco.cc/people/hagen-kennecke/), [Kathy S. Albain](https://onco.cc/people/kathy-albain/), [Mariana Chavez-MacGregor](https://onco.cc/people/mariana-chavez-macgregor/), [Michael LeBlanc](https://onco.cc/people/michael-leblanc/), [Neeraj Agarwal](https://onco.cc/people/neeraj-agarwal/), [Primo N. Lara Jr.](https://onco.cc/people/primo-lara/), [Priyanka Sharma](https://onco.cc/people/priyanka-sharma/), [Virginia Sun](https://onco.cc/people/virginia-sun/)
- key papers: [SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma](https://onco.cc/key-papers/paper-swog-s0809-adjuvant-chemoradiation-jco-2015/), [SWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults](https://onco.cc/key-papers/paper-swog-s1826-nivolumab-avd-nejm-2024/)
- roadmaps: [Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials](https://onco.cc/roadmaps/gallbladder-cancer-roadmap/), [Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on](https://onco.cc/roadmaps/trial-modernisation-roadmap/)
- ideas: [A fixed share of trial-group funding for getting proven care to patients](https://onco.cc/ideas/idea-fund-implementation-quota/), [A permanent neutral non-profit sponsor for multi-company platform trials](https://onco.cc/ideas/idea-fund-neutral-platform-sponsor/), [A publicly held library of investigational drugs available for academic combination trials](https://onco.cc/ideas/idea-tr2-public-combination-formulary/), [A randomised trial of adjuvant chemoradiation after margin-positive or node-positive gallbladder cancer resection](https://onco.cc/ideas/idea-gbc-randomised-adjuvant-chemoradiation-r1-node-positive/), [Follow every trial participant for 30 years through registry linkage](https://onco.cc/ideas/idea-data-registry-follow-up-of-trial-participants/)
- bottlenecks: [Older and multimorbid patients are excluded and undertreated](https://onco.cc/bottlenecks/b-aging-comorbidity/), [Trials do not represent the people who get cancer](https://onco.cc/bottlenecks/b-trial-diversity/), [Trials enrol too few, too slowly](https://onco.cc/bottlenecks/b-trial-enrolment/)

---
JSON: https://onco.cc/api/v1/entities/swog.json